Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.190
0.00 (0.00%)
Oct 23, 2025, 4:00 PM EDT - Market closed
Heron Therapeutics Revenue
Heron Therapeutics had revenue of $37.20M in the quarter ending June 30, 2025, with 3.26% growth. This brings the company's revenue in the last twelve months to $149.69M, up 9.78% year-over-year. In the year 2024, Heron Therapeutics had annual revenue of $144.29M with 13.57% growth.
Revenue (ttm)
$149.69M
Revenue Growth
+9.78%
P/S Ratio
1.22
Revenue / Employee
$1,227,000
Employees
122
Market Cap
218.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 144.29M | 17.24M | 13.57% |
| Dec 31, 2023 | 127.04M | 19.37M | 17.99% |
| Dec 31, 2022 | 107.67M | 21.33M | 24.70% |
| Dec 31, 2021 | 86.35M | -2.29M | -2.59% |
| Dec 31, 2020 | 88.64M | -57.33M | -39.28% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
HRTX News
- 2 days ago - Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - GlobeNewsWire
- 2 months ago - Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value - PRNewsWire
- 2 months ago - Heron Therapeutics, Inc. (HRTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress - PRNewsWire
- 2 months ago - Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile - PRNewsWire
- 2 months ago - Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 - PRNewsWire
- 3 months ago - Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 - PRNewsWire
- 6 months ago - Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 - Seeking Alpha